| Pegvisomant: current and potential novel therapeutic applications. | |
| | |
MedLine Citation:
|
PMID: 19916734 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Pegvisomant is a genetically engineered molecule, which exhibits specific growth hormone (GH) antagonism by directly interacting with the GH receptor. It is currently licensed for the treatment of acromegaly where surgery and medical therapy with somatostatin analogues have failed. OBJECTIVE: To delineate the role of pegvisomant in the treatment of acromegaly and its novel application in other areas of clinical medicine where suppression of GH action may be of therapeutic benefit. METHODS: A literature review from PubMed- and EMBASE-listed publications and the web-sites of licensing organisations for medicinal products. CONCLUSION: Pegvisomant is currently used as a second line therapy in the management of acromegaly. It is highly effective in suppressing the metabolic effects of elevated GH levels when used alone or in combination with somatostatin analogues. However, its long term efficacy and safety for this indication has yet to be established. Preliminary data indicate that pegvisomant may have a role in management of type 1 diabetes with beneficial effects on insulin sensitivity and in preventing the progression of microvascular complications. Additional roles as an adjunct to cancer chemotherapy regimens and for the diagnosis of GH deficiency have been proposed, but have yet to be confirmed. |
| | |
Authors:
|
G N Ajay Thankamony; David B Dunger; Carlo L Acerini |
Related Documents
:
|
19645644 - The general practice experience of the swine flu epidemic in victoria--lessons from the... 19889654 - The role of echocardiography in guiding management in dilated cardiomyopathy. 2649644 - Interventional dysrhythmia management and the role of laser. 19966704 - Flexible cystoscopy: a revolution in urological practice. 11305604 - Changes in the dissolution of tolbutamide by a traditional chinese medicine, sho-saiko-... 16934204 - Common tendinopathies in the upper and lower extremities. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on biological therapy Volume: 9 ISSN: 1744-7682 ISO Abbreviation: Expert Opin Biol Ther Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-11-17 Completed Date: 2010-01-26 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101125414 Medline TA: Expert Opin Biol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1553-63 Citation Subset: IM |
Affiliation:
|
University of Cambridge, Department of Paediatrics, Cambridge, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acromegaly
/
drug therapy*,
metabolism Animals Antineoplastic Agents / therapeutic use Diabetes Mellitus, Type 1 / drug therapy Diabetic Angiopathies / drug therapy Hormone Antagonists / adverse effects, diagnostic use, therapeutic use* Human Growth Hormone / adverse effects, analogs & derivatives*, diagnostic use, therapeutic use Humans Hypoglycemic Agents / therapeutic use Pituitary Diseases / diagnosis, metabolism Receptors, Somatotropin / antagonists & inhibitors*, metabolism Signal Transduction / drug effects* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Hormone Antagonists; 0/Hypoglycemic Agents; 0/Receptors, Somatotropin; 0/pegvisomant; 12629-01-5/Human Growth Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Trastuzumab for gastric cancer.
Next Document: A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer.